Alzinova in BioStock Article (in Swedish)

Alzinova’s lead candidate ALZ-101 is being developed as a therapeutic vaccine against Alzheimer’s disease. In October 2021, the first patient was recruited to the company’s Phase Ib clinical trial with ALZ-101 and recently the company received the go-ahead to continue the study following a positive safety statement from the independent safety group DSMB. In doing so, the world’s first oligomer-specific vaccine in clinical development takes another step forward.

Read the article (in Swedish):

Alzinova lägger grunden för nästa utvecklingssteg